Men's Health (J Mulhall, Section Editor)

Current Urology Reports

, Volume 14, Issue 4, pp 269-278

First online:

Daily Dosing of PDE5 Inhibitors: Where Does it Fit in?

  • King Chien Joe LeeAffiliated withDepartment of Urology, National University Hospital Email author 
  • , Gerald B. BrockAffiliated withDivision of Urology, St Joseph’s Health Care, University of Western Ontario Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


To provide a critical contemporary review of daily PDE5-inhibitor (PDE5-I) use in urological and nonurological conditions. PDE5-Is can be taken up to once a day. However, at present only tadalafil is approved for use in both erectile dysfunction (ED) and benign prostate hyperplasia (BPH) with lower urinary tract symptoms (LUTS). Evolving research in penile rehabilitation, Peyronie’s disease, male infertility, pulmonary arterial hypertension, muscular dystrophy and Raynaud’s phenomenon shows these therapeutic areas may also benefit from PDE5i therapy. This review examines the role of chronic PDE5 inhibition in ED, BPH-LUTS and other therapeutic targets which may shape our clinical practice in the years to come.


PDE5 inhibitors Daily use LUTS Benign prostate hyperplasia Erectile dysfunction